Market Overview

Lungs are one of the primary organ involved in the respiration system and an injury to these organs impede normal functioning along with healthy growth and development of the human body. The lung injury drugs utilization can be due to direct or indirect causes including trauma, infections, pressure exerted on ribs, sepsis, transfusions, toxic substances, aspiration, inhalation of smoke or gases, overuse of medication and surgery.

The lung injury drugs prescribed to the patients are categorized in different classes and vary in their mechanism and mode of action. Depending on the symptoms observed by the pulmonologist along with medical history, genetic factors, lifestyle and unfavorable environmental factors, the therapy can be designed to treat the patients suffering from acute lung injury, pulmonary edema, pulmonary embolism, pulmonary laceration and pneumothorax.

The acute lung injury gives rise to respiratory failure and ultimately death if undiagnosed. Lung injury drugs help reduce the inflammation by repairing the cell lines and relieving from the associated pain.

Rising prevalence of patient pool suffering from chronic obstructive pulmonary diseases is the key factor propelling the revenue growth of lung injury drugs market over the forecast period. The lung injury drugs are expected to generate demand due to rising surgical treatments in most of the markets. The lung cancer treatments are on rise and anticipated to drive the growth of the lung injury drugs market. The FDA/EMA approvals for rare diseases associated with lungs are expected to grow the lung injury drugs market.

The inhalation of tobacco and cannabinoid intoxicants through vapes and other instruments may rise the number of patients demanding for the lung injury drugs. The collaborative research for new drug development, awareness through diagnostic techniques and increasing trend of universal health coverage in the newly developing markets are supposed to drive the lung injury drugs markets in spite of the fluctuating government policies.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Market Segmentation

Drug Class	Corticosteroids Kinase inhibitors Antibiotics
Route of administration	Oral Nasal Intravenous
Distribution Channel	Hospitals Clinics Pharmacies Others
Region	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa